Best Vaccine Stocks

On Tuesday, Johnson & Johnson announced that its combination treatment, which does not involve chemotherapy, significantly helps to prolong the lives of patients with a specific type of lung cancer when compared to AstraZeneca's popular drug, Tagrisso.

The median overall survival improvement is expected to be over one year. This is the first treatment to show a survival benefit compared to the current standard care for patients with EGFR-mutated lung cancer. Johnson & Johnson recently shared positive results from the Phase 3 MARIPOSA study, which tested RYBREVANT® and LAZCLUZE™ as a first-line therapy for advanced non-small cell lung cancer.

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you experienced a loss from your investment in AstraZeneca PLC (NASDAQ:AZN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=121173&wire=1 or reach out to Joseph E. Levi, Esq.

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, informs investors about a class action lawsuit filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and some of its executives. Class Definition This lawsuit aims to seek compensation for damages due to alleged breaches of federal securities laws on behalf of all individuals and entities that bought or acquired AstraZeneca securities from February 23, 2022, to December 17, 2024, inclusive (the "Class Period").

SAN DIEGO--(BUSINESS WIRE)--The lawsuit claims that the defendants made misleading statements about AstraZeneca's business and future, which caused its stock to be traded at higher prices than it should have been.

On January 7, 2025, Levi & Korsinsky, LLP informed investors in AstraZeneca PLC about a class action securities lawsuit. This lawsuit aims to help AstraZeneca investors who suffered losses due to alleged securities fraud that occurred between February 23, 2022, and December 17, 2024.

GSK PLC (LSE:GSK, NYSE:GSK) has received significant support for its experimental drug GSK5764227 (GSK'227), aimed at treating a rare and aggressive bone cancer known as osteosarcoma. The US Food and Drug Administration (FDA) has given this treatment Breakthrough Therapy Designation, which is for patients whose cancer has come back after at least two previous treatments.

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you experienced a loss from your investment in AstraZeneca PLC (NASDAQ:AZN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=121107&wire=1 or reach out to Joseph E. Levi, Esq.

Kahn Swick & Foti, LLC ("KSF") and its partner, former Louisiana Attorney General Charles C. Foti, Jr., want to remind investors that they have until February 21, 2025, to submit lead plaintiff applications in a securities class action lawsuit against AstraZeneca PLC (NasdaqGS:AZN). This applies to those who bought the Company's securities between February 23, 2022, and December 17, 2024, during the "Class Period."